About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker SGMOQ · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 3, 2026Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fib…
NCT06980948 · Chronic Neuropathic Pain
ST-503, Sham (No Treatment)
SGMOQ
Sangamo Therapeutics
Phase 1/2Suspended
was recruiting
27Jul 2027Registry ↗
Oct 27, 2026Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With F…
NCT04046224 · Fabry Disease
ST-920
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed36Apr 10, 2025Registry ↗
Aug 20, 2026Long-Term Follow-up of Subjects Who Were Treated With ST-920
NCT05039866 · Fabry Disease, Fabry Disease, Cardiac Variant
ST-920
SGMOQ
Sangamo Therapeutics
—Active, not recruiting32Mar 2029Registry ↗
Aug 13, 2026Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
NCT04628871 · Hemophilia B, Mucopolysaccharidosis I
SB-318, SB-913
SGMOQ
Sangamo Therapeutics
—Terminated13Jun 17, 2026Registry ↗
Jul 2, 2026Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal T…
NCT04817774 · Kidney Transplant Rejection, End Stage Renal Disease
TX200-TR101
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed26Jul 11, 2024Registry ↗
Dec 4, 2025Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
NCT05987527 · Kidney Transplant Rejection, End Stage Renal Disease
Blood sample
SGMOQ
Sangamo Therapeutics
—Active, not recruiting11Jun 11, 2039Registry ↗
Nov 12, 2025Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BI…
NCT05145062 · Blood and Lymphatic Diseases
BIVV003, ST-400
SGMOQ
Sangamo Therapeutics
—Active, not recruiting8Jul 14, 2038Registry ↗
Sep 12, 2025A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic St…
NCT03653247 · Sickle Cell Disease
Plerixafor, Busulfan
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed7Jul 17, 2025Registry ↗
Jul 19, 2024Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With…
NCT02695160 · Hemophilia B
SB-FIX
SGMOQ
Sangamo Therapeutics
Phase 1Terminated1Apr 19, 2021Registry ↗
Jan 26, 2024Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
NCT04201782 · HIV-1-infection
There are no disallowed treatments
SGMOQ
Sangamo Therapeutics
—Terminated38Jul 17, 2023Registry ↗
Dec 14, 2023A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dep…
NCT03432364 · Transfusion Dependent Beta-thalassemia
ST-400 Investigational product
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed5Nov 17, 2022Registry ↗
Jan 26, 2023Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subj…
NCT02702115 · MPS I
SB-318
SGMOQ
Sangamo Therapeutics
Phase 1/2Terminated3Nov 3, 2021Registry ↗
Nov 10, 2022Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Pa…
NCT00400634 · Idiopathic Parkinson's Disease
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturi…
SGMOQ
Sangamo Therapeutics
Phase 2Completed58Nov 2008Registry ↗
Nov 10, 2022Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
NCT00252850 · Parkinson's Disease
CERE-120: AAV2-NTN
SGMOQ
Sangamo Therapeutics
Phase 1Completed12Mar 2007Registry ↗
Nov 10, 2022CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00087789 · Alzheimer's Disease
CERE-110: Adeno-Associated Virus Delivery of NGF
SGMOQ
Sangamo Therapeutics
Phase 1Completed10May 2010Registry ↗
Oct 25, 2022Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subj…
NCT03041324 · Mucopolysaccharidosis II, MPS II
SB-913
SGMOQ
Sangamo Therapeutics
Phase 1/2Terminated9May 7, 2021Registry ↗
May 23, 2022Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT01079325 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
SB-509, Saline
SGMOQ
Sangamo Therapeutics
Phase 2Completed170May 2015Registry ↗
May 24, 2021Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
NCT01543152 · HIV
SB-728-T, SB-728-T
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed26Jul 7, 2017Registry ↗
Mar 19, 2021Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
NCT02225665 · Human Immunodeficiency Virus (HIV)
SB-728mR-T, SB-728mR-T
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed8Jun 2018Registry ↗
Dec 21, 2020Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Dise…
NCT00876863 · Alzheimer's Disease
CERE-110: Adeno-Associated Virus injection Surgery, Placebo…
SGMOQ
Sangamo Therapeutics
Phase 2Completed49Aug 13, 2015Registry ↗
Apr 16, 2020Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
NCT00985517 · Idiopathic Parkinson's Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sha…
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed57Nov 9, 2014Registry ↗
Sep 20, 2019Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-I…
NCT01252641 · HIV, HIV Infection
SB-728-T
SGMOQ
Sangamo Therapeutics
Phase 1/2Completed21Dec 2014Registry ↗
Mar 13, 2015Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc F…
NCT01044654 · HIV Infection, HIV Infections
SB-728-T
SGMOQ
Sangamo Therapeutics
Phase 1Completed19Dec 2014Registry ↗

23 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:55 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances